Access cutting-edge primary membranous nephropathy treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access primary membranous nephropathy specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related primary membranous nephropathy treatment provided free
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
Sponsor: BeiGene
Check if you qualify for this primary membranous nephropathy clinical trial in Palo Alto, CA
If you're searching for primary membranous nephropathy treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary membranous nephropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.